PHVS Insider Peng Lu Sells Shares as Analysts Maintain Optimism
Chief Medical Officer Peng Lu sold 300 shares of PHVS on June 18, 2026.
Key Points
- Peng Lu, PHVS Chief Medical Officer, sold 300 shares on June 18, 2026, without a planned sale.
- PHVS shares traded near $33 on Wednesday, with analysts maintaining 'buy' ratings and targets up to $74.
- General Atlantic holds 8,031,252 shares of PHVS, while FMR LLC slightly reduced its position by 114,686 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Peng Lu, the Chief Medical Officer of PHVS, sold 300 shares of the company. This transaction wasn't part of a pre-arranged plan. The sale occurred as PHVS shares traded around $33.
Insider Buying and Selling at Pharvaris N.V.
Peng Lu, PHVS's Chief Medical Officer, was active on June 18, 2026, selling 300 shares without a pre-planned sale. Additionally, on June 15, 2026, Chief Executive Officer Berndt Modig sold 2,291 shares at an average price of $31.07 as part of a planned transaction.
Other Institutional Activity in PHVS
General Atlantic, L.P. holds a substantial stake in PHVS, with 8,031,252 shares valued at approximately $226.9 million, maintaining its position with no change. FMR LLC trimmed its holdings by 114,686 shares, ending with 6,284,472 shares worth about $177.5 million, marking a 1.8% decrease. Other major holders like Foresite Capital Management IV, LLC, Venbio Partners LLC, and Viking Global Investors LP kept their positions steady.
Pharvaris N.V. Stock Down 6.6%
Shares of PHVS traded near $33 on Wednesday. The stock has shown volatility, with a 52-week range yet unspecified here. Despite this, the market remains optimistic about its potential, as reflected in the interest from institutional investors.
$PHVS stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts are bullish on PHVS, with Citizens maintaining a 'buy' rating and a $74 price target as of May 13, 2026. Wolfe Research initiated coverage with a 'buy' rating and a $42 target on April 9, 2026. Similarly, Wedbush and RBC Capital have maintained 'buy' ratings with targets of $42 and $51, respectively.
Bottom Line
Insider transactions like Peng Lu's sale provide insights into executive sentiment but don't necessarily predict stock performance. Investors often track these moves for potential signals. Analyst support remains strong for PHVS, with several firms maintaining 'buy' ratings and optimistic targets, suggesting continued confidence in the company's prospects.
Get Pharvaris N.V. alerts
New 13F filings, insider trades, and analyst moves on $PHVS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.